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Abstract 
Background: Data from clinical studies show that artemether-lumefantrine (AL) is effective and well tolerated in 
adults and children with uncomplicated Plasmodium falciparum malaria. However, data on effectiveness and safety of 
AL in patients in non-endemic settings are limited.
Methods: A 5-year surveillance plan included all AL-treated adult and paediatric patients with confirmed or sus-
pected P. falciparum malaria in the USA, as reported to the National Malaria Surveillance System at the Centers for 
Disease Control and Prevention. Descriptive analyses included demographics, baseline characteristics, clinical effec-
tiveness, and safety. From May 2010 to April 2015, demographics and baseline characteristics were collected for 203 
patients and safety data for 108 patients. Treatment effectiveness data at day 7 were collected for 117 patients and at 
day 28 for 98 patients.
Results: The majority of patients were male (58.6 %), Black (62.6 %), non-Hispanic (92.6 %), and likely malaria non-
immune (80.8 %). The median age was 32 (range 1–88) years and the median body mass index was 25.5 (range 
13.8–42.4) kg/m2. All patients with effectiveness data had confirmed (n = 116) or suspected (n = 1) malaria. The over-
all cure rate for patients treated with AL was 91.5 % (95 % CI 84.8–95.8 %) at day 7 and 96.9 % (95 % CI 91.3–99.4 %) at 
day 28. Adverse events were reported in four (3.7 %) patients, and there were no new or unexpected safety signals.
Conclusion: AL was effective and well tolerated in the treatment of likely non-immune patients with P. falciparum 
malaria.
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Background
Malaria is the most common febrile disease resulting 
in post-travel hospitalization, and artemisinin-based 
therapy is considered to be the fastest and most potent 
current anti-malarial treatment [1, 2]. Artemether-
lumefantrine (AL) (Coartem®, Novartis Pharma AG, 
Basel, Switzerland) is a fixed-dose combination of 20 mg 
artemether and 120 mg lumefantrine. Both components 
are blood schizonticides with complementary phar-
macokinetic profiles and dissimilar modes of action, 
thus providing synergistic anti-malarial activity [3–5]. 
Artemether is absorbed rapidly and has an elimination 
half-life of around 1 h. It clears most of the parasite bio-
mass, providing fast resolution of symptoms during the 
acute treatment period. Longer acting lumefantrine, with 
a half-life of 3 to 6  days, has a variable absorption rate 
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that improves when administered with fat and is more 
effective in the recovery phase, eliminating residual para-
sites. The efficacy and safety of AL has been established 
in adult and paediatric patients in clinical trials, mainly 
in malaria-endemic regions such as Southeast Asia [6–
11], sub-Saharan Africa [12–20] and Latin America [21]. 
However, effectiveness and safety data for the treatment 
of uncomplicated malaria in non-endemic countries are 
limited.
In 2006, the World Health Organization initially rec-
ommended that artemisinin-based combination therapy 
(ACT) be used as first-line treatment for uncomplicated 
malaria [22]. Since then, AL has been widely adopted 
throughout malaria-endemic countries, especially in sub-
Saharan Africa, as a first- or second-line treatment for 
uncomplicated Plasmodium falciparum malaria. Addi-
tionally, Coartem® has also been registered in various 
non-endemic countries including the USA [5, 23, 24]. It 
received approval from the US Food and Drug Admin-
istration (FDA) in April 2009, becoming the first ACT 
available for the treatment of uncomplicated falciparum 
malaria in the USA [24], and is recommended by the 
US Centers for Disease Control and Prevention (CDC) 
as a treatment option for uncomplicated malaria. Other 
treatment options for uncomplicated falciparum malaria 
include atovaquone-proguanil; quinine sulfate plus either 
doxycycline, tetracycline or clindamycin; mefloquine; 
and chloroquine in the case of malaria acquired in areas 
with chloroquine-sensitive parasites [25].
In the context of the USA’s approval of Coartem®, the 
FDA required that Novartis conduct a descriptive sur-
veillance project on the use of AL tablets in non-immune 
travellers as a post-marketing requirement. This project 
was conducted through collaboration between Novartis 
and CDC by which AL-treated malaria cases in the USA 
were captured in the National Malaria Surveillance Sys-
tem (NMSS). This report aims to describe the demo-
graphics, baseline characteristics, clinical effectiveness, 
and safety outcomes for patients treated with AL in both 
US and foreign residents.
Methods
Cases
Malaria is a mandatory reportable disease in the USA. 
Cases are reported by healthcare providers or laboratory 
staff to local and state health departments, and reports 
are in turn transmitted to CDC through the NMSS [26].
Any patient with malaria reported to CDC who had 
received AL treatment was included in this analysis. 
Patients who were diagnosed by microscopy or by poly-
merase chain reaction (PCR) were considered as con-
firmed cases, while those diagnosed by a rapid diagnostic 
test (RDT) or clinically with no (or missing) microscopy 
were considered as suspected cases. Both confirmed and 
suspected cases were included in all analyses. However, 
patients with a positive RDT result followed by negative 
microscopy or a clinical diagnosis only were considered 
as non-malaria cases (i.e., neither confirmed nor sus-
pected) and were only included in the descriptive analy-
ses of demographics, baseline characteristics and safety.
Surveillance study design
Patients treated with AL for confirmed or clinically sus-
pected malaria were reported to CDC as a routine public 
health surveillance activity. Data collection was planned 
for a total of 5  years. Information was captured using 
the CDC Malaria Case Surveillance Report form [27]. 
Contact with the treating physician was initiated by tel-
ephone either when the treating physician sought guid-
ance on treatment of a patient with malaria or after the 
malaria case was passively reported. This report includes 
a descriptive analysis of data covering the period from 
May 2010 to April 2015.
Surveillance study assessments
Patient demographic and baseline characteristics 
included age, gender, race, ethnicity, height, weight, and 
likely malaria immune status. Persons were considered 
to be likely semi-immune if they were recent immigrants 
from or residents of malaria-endemic countries who were 
visiting the USA when they were diagnosed with malaria. 
Residents of non-endemic countries and US travellers 
were considered likely non-immune. Clinical effective-
ness was assessed in cases with available follow-up infor-
mation on the Malaria Case Surveillance Report form. 
Resolution of clinical signs and symptoms after start of 
AL treatment was assessed with the following question: 
“Did all signs or symptoms of malaria resolve without any 
additional malaria treatment within 7  days after treat-
ment start?” For patients with an answer ‘yes’ to this 
question, effectiveness at day 28 was assessed using the 
follow-up question: “Did the patient experience recur-
rence of signs or symptoms of malaria during the 4 weeks 
after starting malaria treatment?”
Statistical analysis
Data analysis was not based on a specific a priori statis-
tical hypothesis and was simply descriptive. Summary 
statistics were presented for quantitative variables, and 
counts and percentages were calculated for categorical 
data. For the day 7 and day 28 cure rates, the proportions 
of cured patients and two-sided 95  % confidence inter-
vals were calculated using exact Pearson-Clopper limits 
[28]. The proportion of cured patients was based on all 
patients with available effectiveness information. Effec-
tiveness data were further stratified by age (≤16  years, 
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17–64 years, ≥65 years), body mass index [(BMI) < 25 kg/
m2, ≥25  kg/m2], likely malaria immune status, malaria 
species (P.  falciparum, other, undetermined), and status 
of malaria diagnosis (confirmed, suspected).
Results
A total of 203 AL-treated cases were reported from 
May 2010 to April 2015. Figure 1 shows the proportion 
of patients treated with AL per year based on the total 
number of confirmed malaria cases reported in the USA 
per year in the NMSS. All cases were imported (i.e., US 
travellers or foreign visitors), with 61.1 % of the malaria 
infections acquired in West Africa. The remaining 38.9 % 
of infections were acquired in East Africa, Central Africa, 
South Africa, the Caribbean, and South America. The 
majority of patients were aged 17–64 years, male, Black, 
non-Hispanic, and likely malaria non-immune. Some 
patients were missing information on variables such 
as height and weight (i.e., 94 patients did not have a 
recorded height and 71 patients did not have a recorded 
weight). Therefore, it was only possible to calculate the 
BMI for 107 patients (Table 1).
Table  2 outlines day 7 and day 28 cure rates. One 
patient was excluded from the effectiveness analysis 
because the patient had a positive RDT followed by a 
negative microscopy. For the day 7 cure rate, effective-
ness data were available for 117 of 202 patients with 
confirmed (n = 116) or suspected (n = 1) malaria due to 
P. falciparum or another species. For the day 28 cure rate, 
effectiveness data were available for 98 patients with con-
firmed malaria. Effectiveness results were analysed with 
missing effectiveness data excluded.
At day 7, the overall cure rate was 91.5  % (107/117). 
Out of the ten patients who did not resolve their malaria 
by day 7, seven had severe malaria at baseline and should 
not have received AL to begin with, one had an adverse 
Fig. 1 Percentage of confirmed malaria cases treated with 
artemether-lumefantrine in the USA by year (2010–2013)
Table 1 Demographic and baseline characteristics
Characteristic N = 203a
Age (years)
 Mean ± SD 34.2 ± 18.5
 Median 32
 Range 1–88
Age (years) category, n (%)
 ≤16 32 (15.8)
 17–64 157 (77.3)
 ≥65 14 (6.9)
Gender, n (%)
 Male 119 (58.6)
 Female 84 (41.4)
Race, n (%)
 Black or African American 127 (62.6)
 Caucasian 55 (27.1)
 Asian 9 (4.4)
 Native Hawaiian or Other Pacific Islander 2 (1.0)
 American Indian or Alaska Native 1 (0.5)
 Missing 9 (4.4)
Ethnicity, n (%)
 Hispanic or Latino 2 (1.0)
 Not Hispanic or Latino 188 (92.6)
 Missing 13 (6.4)
Height (cm), N = 109
 Mean ± SD 165.7 ± 21.8
 Median 172.7
 Range 80.0–198.1
Weight (kg), N = 132
 Mean ± SD 71.1 ± 23.8
 Median 72.7
 Range 9.0–144.1
BMI (kg/m2), N = 107
 Mean ± SD 25.6 ± 5.9
 Median 25.5
 Range 13.8–42.4
BMI (kg/m2) category, n (%)
 <25 50 (24.6)
 ≥25 57 (28.1)
 Missing 96 (47.3)
Immune status, n (%)
 Likely non-immune 164 (80.8)
 Likely semi-immune 39 (19.2)
Malaria species, n (%)
 P. falciparum 160 (78.8)
 Other Plasmodium species (including P. vivax, P. ovale, P. 
malariae)
26 (12.8)
 Undetermined 17 (8.4)
Malaria diagnosis, n (%)
 Confirmed by microscopy 195 (96.1)
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event of nausea that was considered by the treating physi-
cian to be related to AL and was switched to atovaquone-
proguanil, one was rehospitalized because of haemolytic 
anaemia thought to be due to persistent malaria and was 
discharged on quinine and doxycycline, and one did not 
complete the treatment course due to a supply short-
age at the treating hospital. At day 28, clinical effective-
ness data were available for 98 patients and the overall 
cure rate was 96.9 % (95/98). Three patients experienced 
a recurrence of signs or symptoms of malaria within 
28  days. Of the 19 patients who were assessed at day 7 
but not at day 28, data were missing for nine and were 
not collected for the ten patients who did not resolve at 
day 7 and were mainly switched to other anti-malarials. 
The day 7 (91.5 %) cure rate is not a true representation 
of the effectiveness of AL as at least seven patients should 
not have received AL for treatment of their malaria. 
Notably, although 22 other patients with severe malaria 
resolved upon receiving AL without further treatment, 
AL is indicated only for the treatment of uncomplicated 
falciparum malaria.
Adverse events (AEs) were reported in four (3.7  %) 
patients (Table  3), including three AEs (two anaemia 
and one nausea) suspected to be related to AL. Anae-
mia was reported as a serious adverse event (SAE) in 
two (1.9  %) patients. One had haemolytic anaemia and 
was rehospitalized, and the second received an outpa-
tient blood transfusion due to ongoing haemolysis. Both 
of these SAEs were considered by the treating physicians 
to be related to ineffective treatment with AL, but there 
was no evidence of treatment failure in either case. Fol-
low-up information was provided only for the first case. 
The patient experienced a haemoglobin decrease of 3 g/
dl with a concurrent increase in lactate dehydrogenase 
and decrease in haptoglobin 12  days after the first dose 
of AL, which is consistent with the post-artemisinin 
delayed haemolysis syndrome [29]. Of note, this syn-
drome seems to occur in patients with hyperparasitaemia 
who should not be treated with oral therapy such as AL. 
The second patient was incorrectly diagnosed as hav-
ing only falciparum malaria at baseline while the patient 
was actually co-infected with Plasmodium  vivax. AL 
cleared the original infection, but one month later, after 
re-appearance of symptoms, the patient was treated with 
BMI, body mass index, calculated in kg/m2  as weight (in pounds) × 703/
(height)2 (in inches); SD, standard deviation
a N = 203 unless indicated otherwise
Table 1 continued
Characteristic N = 203a
 Confirmed by PCR 6 (3.0)
 Suspected 1 (0.5)
 RDT positive (microscopy negative) 1 (0.5)
Table 2 Day 7 and day 28 cure rates
CI, confidence interval, calculated according to the exact Pearson-Clopper method
Day 7 cure rate (N = 117) Day 28 cure rate (N = 98)
n (%) 95 % CI n (%) 95 % CI
Overall 107 (91.5) 84.8–95.8 95 (96.9) 91.3–99.4
By age (years)
 ≤16 14/15 (93.3) 68.1–99.8 11/12 (91.7) 61.5-99.8
 17–64 88/96 (91.7) 84.4–96.3 78/80 (97.5) 91.3–99.7
 ≥65 5/6 (83.3) 35.9–99.6 6/6 (100.0) 54.1–100.0
By BMI (kg/m2)
 <25 35/39 (89.7) 75.8–97.1 28/30 (93.3) 77.9–99.2
 ≥25 39/40 (97.5) 86.8–99.9 38/39 (97.4) 86.5–99.9
 Unknown/not reported 33/38 (86.8) 71.9–95.6 29/29 (100.0) 88.1–100.0
By immune status
 Likely non-immune 89/99 (89.9) 82.2–95.1 78/81 (96.3) 89.6–99.2
 Likely semi-immune 18/18 (100.0) 81.5–100.0 17/17 (100.0) 80.5–100.0
By malaria species
 P. falciparum 81/90 (90.0) 81.9–95.3 73/75 (97.3) 90.7–99.7
 Other Plasmodium species (including P. vivax, P. ovale, P. malariae) 18/18 (100.0) 81.5–100.0 16/17 (94.1) 71.3–99.9
 Undetermined 8/9 (88.9) 51.8–99.7 6/6 (100.0) 54.1–100.0
By status of malaria diagnosis
 Confirmed 106/116 (91.4) 84.7–95.8 95/98 (96.9) 91.3–99.4
 Suspected 1/1 (100.0) 2.5–100.0 0/0 (0.0) –
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atovaquone-proguanil, doxycycline and primaquine, and 
the vivax co-infection was cleared.
Cases are often reported to CDC long after they 
occurred or were originally notified (due to delays from 
the applicable state or treatment facility), and the lag time 
between occurrence of a case and its reporting to CDC 
can vary from a few days to 1 year or longer. Data avail-
able from 150 cases showed that they were reported to 
CDC on average 84 (range 1–733) days after the onset of 
signs and symptoms. As a result, there are possibly addi-
tional cases that may have been applicable to the time-
frame of this project but were excluded due to a delay in 
reporting.
The delay in case reporting and retrospective data col-
lection, small sample size, and incomplete data mainly 
because of loss to follow-up are all inherent limitations 
of this surveillance project. Other limitations include the 
non-comparative and non-randomized methods of data 
collection, unsupervised treatment, and clinical effective-
ness and safety outcomes that were solely determined 
by the healthcare provider. Therefore, effectiveness data 
from this surveillance could hardly be considered as 
robust as those from some effectiveness studies con-
ducted in endemic countries [15, 19]. Despite these limi-
tations, such data represent the best available outcomes 
data for AL treatment in the USA and correlate well with 
results reported from other settings including those from 
prospective interventional studies.
Conclusion
AL was effective and well tolerated in the treatment of 
likely non-immune patients in the USA with falciparum 
malaria.
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